Skip to main content
logo
Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
1.870
+0.060 (3.31%)
At close: Oct 27, 2026, 4:00 PM EDT
1.850
-0.020 (-1.07%)
After-hours: Oct 27, 2026, 7:30 PM EDT

Grace Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Oct '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Market Capitalization
397231322154
Market Cap Growth
-9.36%129.06%-2.84%56.90%-62.03%-55.00%
Enterprise Value
2653207-108
Last Close Price
1.814.632.283.422.767.32

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Oct '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PB Ratio
0.611.120.470.520.300.50
P/TBV Ratio
3.204.901.812.581.102.12

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Oct '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Debt / Equity Ratio
----0.010.00
Net Debt / Equity Ratio
-0.28-0.27-0.33-0.37-0.40-0.40
Net Debt / EBITDA Ratio
1.331.531.332.041.523.87
Net Debt / FCF Ratio
1.341.911.491.861.722.52
Quick Ratio
11.027.9211.5314.098.4113.56
Current Ratio
11.478.1011.7714.268.5913.89
Return on Equity (ROE)
-36.19%-11.94%-14.91%-19.82%-48.15%-11.98%
Return on Assets (ROA)
-10.81%-9.99%-14.35%-9.25%-10.96%-7.94%
Return on Capital Employed (ROCE)
-21.20%-17.20%-23.80%-15.70%-24.00%-9.70%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Oct '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Earnings Yield
-64.19%-10.88%-30.59%-39.92%-206.80%-18.17%
FCF Yield
-25.74%-12.38%-47.65%-38.38%-77.64%-31.90%
Buyback Yield / Dilution
-26.32%-36.59%-26.85%-28.16%-21.09%-148.46%
SEC Filings: 10-K · 10-Q